

# Hereceptin Biosimilar-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/HE4E733FCD4EN.html

Date: December 2017 Pages: 148 Price: US\$ 3,480.00 (Single User License) ID: HE4E733FCD4EN

# Abstracts

**Report Summary** 

Hereceptin Biosimilar-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hereceptin Biosimilar industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Hereceptin Biosimilar 2013-2017, and development forecast 2018-2023 Main market players of Hereceptin Biosimilar in EMEA, with company and product introduction, position in the Hereceptin Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges

The report segments the EMEA Hereceptin Biosimilar market as:

EMEA Hereceptin Biosimilar Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East Africa

EMEA Hereceptin Biosimilar Market: Product Type Segment Analysis (Consumption



Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Tablet Capsule

EMEA Hereceptin Biosimilar Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Pharmaceuticals Healthcare Others

EMEA Hereceptin Biosimilar Market: Players Segment Analysis (Company and Product introduction, Hereceptin Biosimilar Sales Volume, Revenue, Price and Gross Margin):

Mylan N.V. AryoGen Biopharma Genor Biopharma Celltrion Inc. Amgen Inc. Mabion S.A. The Instituto Vital Brazil F. Hoffmann-La Roche AG Biocon Gedeon Richter Plc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



# Contents

### CHAPTER 1 OVERVIEW OF HERECEPTIN BIOSIMILAR

- 1.1 Definition of Hereceptin Biosimilar in This Report
- 1.2 Commercial Types of Hereceptin Biosimilar
- 1.2.1 Tablet
- 1.2.2 Capsule
- 1.3 Downstream Application of Hereceptin Biosimilar
- 1.3.1 Pharmaceuticals
- 1.3.2 Healthcare
- 1.3.3 Others
- 1.4 Development History of Hereceptin Biosimilar
- 1.5 Market Status and Trend of Hereceptin Biosimilar 2013-2023
- 1.5.1 EMEA Hereceptin Biosimilar Market Status and Trend 2013-2023
- 1.5.2 Regional Hereceptin Biosimilar Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Hereceptin Biosimilar in EMEA 2013-2017
- 2.2 Consumption Market of Hereceptin Biosimilar in EMEA by Regions
- 2.2.1 Consumption Volume of Hereceptin Biosimilar in EMEA by Regions
- 2.2.2 Revenue of Hereceptin Biosimilar in EMEA by Regions
- 2.3 Market Analysis of Hereceptin Biosimilar in EMEA by Regions
- 2.3.1 Market Analysis of Hereceptin Biosimilar in Europe 2013-2017
- 2.3.2 Market Analysis of Hereceptin Biosimilar in Middle East 2013-2017
- 2.3.3 Market Analysis of Hereceptin Biosimilar in Africa 2013-2017
- 2.4 Market Development Forecast of Hereceptin Biosimilar in EMEA 2018-2023
- 2.4.1 Market Development Forecast of Hereceptin Biosimilar in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Hereceptin Biosimilar by Regions 2018-2023

### CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Hereceptin Biosimilar in EMEA by Types
- 3.1.2 Revenue of Hereceptin Biosimilar in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe
  - 3.2.2 Market Status by Types in Middle East



3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Hereceptin Biosimilar in EMEA by Types

# CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Hereceptin Biosimilar in EMEA by Downstream Industry4.2 Demand Volume of Hereceptin Biosimilar by Downstream Industry in MajorCountries

- 4.2.1 Demand Volume of Hereceptin Biosimilar by Downstream Industry in Europe
- 4.2.2 Demand Volume of Hereceptin Biosimilar by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Hereceptin Biosimilar by Downstream Industry in Africa
- 4.3 Market Forecast of Hereceptin Biosimilar in EMEA by Downstream Industry

# CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HERECEPTIN BIOSIMILAR

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Hereceptin Biosimilar Downstream Industry Situation and Trend Overview

# CHAPTER 6 HERECEPTIN BIOSIMILAR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Hereceptin Biosimilar in EMEA by Major Players
- 6.2 Revenue of Hereceptin Biosimilar in EMEA by Major Players
- 6.3 Basic Information of Hereceptin Biosimilar by Major Players

6.3.1 Headquarters Location and Established Time of Hereceptin Biosimilar Major Players

6.3.2 Employees and Revenue Level of Hereceptin Biosimilar Major Players

- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

# CHAPTER 7 HERECEPTIN BIOSIMILAR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Mylan N.V. 7.1.1 Company profile



- 7.1.2 Representative Hereceptin Biosimilar Product
- 7.1.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Mylan N.V.
- 7.2 AryoGen Biopharma
  - 7.2.1 Company profile
  - 7.2.2 Representative Hereceptin Biosimilar Product
- 7.2.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of AryoGen Biopharma
- 7.3 Genor Biopharma
- 7.3.1 Company profile
- 7.3.2 Representative Hereceptin Biosimilar Product
- 7.3.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Genor

Biopharma

- 7.4 Celltrion Inc.
  - 7.4.1 Company profile
  - 7.4.2 Representative Hereceptin Biosimilar Product
- 7.4.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Celltrion Inc.

7.5 Amgen Inc.

- 7.5.1 Company profile
- 7.5.2 Representative Hereceptin Biosimilar Product
- 7.5.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Amgen Inc.

7.6 Mabion S.A.

- 7.6.1 Company profile
- 7.6.2 Representative Hereceptin Biosimilar Product
- 7.6.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Mabion S.A.
- 7.7 The Instituto Vital Brazil
  - 7.7.1 Company profile
  - 7.7.2 Representative Hereceptin Biosimilar Product
- 7.7.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of The Instituto Vital Brazil
- 7.8 F. Hoffmann-La Roche AG
  - 7.8.1 Company profile
  - 7.8.2 Representative Hereceptin Biosimilar Product
- 7.8.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of F. Hoffmann-
- La Roche AG
- 7.9 Biocon
  - 7.9.1 Company profile
  - 7.9.2 Representative Hereceptin Biosimilar Product
  - 7.9.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Biocon
- 7.10 Gedeon Richter Plc



7.10.1 Company profile

7.10.2 Representative Hereceptin Biosimilar Product

7.10.3 Hereceptin Biosimilar Sales, Revenue, Price and Gross Margin of Gedeon Richter Plc

# CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HERECEPTIN BIOSIMILAR

- 8.1 Industry Chain of Hereceptin Biosimilar
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

# CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HERECEPTIN BIOSIMILAR

- 9.1 Cost Structure Analysis of Hereceptin Biosimilar
- 9.2 Raw Materials Cost Analysis of Hereceptin Biosimilar
- 9.3 Labor Cost Analysis of Hereceptin Biosimilar
- 9.4 Manufacturing Expenses Analysis of Hereceptin Biosimilar

# CHAPTER 10 MARKETING STATUS ANALYSIS OF HERECEPTIN BIOSIMILAR

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

# CHAPTER 11 REPORT CONCLUSION

# CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation



- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



### I would like to order

Product name: Hereceptin Biosimilar-EMEA Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/HE4E733FCD4EN.html</u>

> Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/HE4E733FCD4EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970